Ask about this productRelated genes to: MAGEA8 antibody
- Gene:
- MAGEA8 NIH gene
- Name:
- MAGE family member A8
- Previous symbol:
- MAGE8
- Synonyms:
- MGC2182, CT1.8
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1994-04-04
- Date modifiied:
- 2015-11-13
Related products to: MAGEA8 antibody
Related articles to: MAGEA8 antibody
- This study aims to identify novel biomarkers for the early diagnosis of lung adenocarcinoma (LUAD), with the goal of facilitating early intervention to improve patient prognosis. - Source: PubMed
Publication date: 2026/01/05
Huang ShuyuGan YuhanZhong RuifangWang SiyingKang YanliChen JinhuaChen FalinChen LiangyuanYou Jianbin - During mammalian spermatogenesis, the cytoskeleton system plays a significant role in morphological changes. Male infertility such as non-obstructive azoospermia (NOA) might be explained by studies of the cytoskeletal system during spermatogenesis. - Source: PubMed
Publication date: 2025/01/25
Hashemi Karoii DanialAzizi HosseinDarvari MaryamQorbanee AliHawezy Dawan Jamal - Melanoma antigen gene (MAGE) families are cancer-testis genes that normally show expression in the testes. However, their expressions have been linked with various types of human cancers, including BC. Therefore, the primary purposes of the present research were to assess the expression of , B, and C genes in Saudi female patients with BC and determine their regulation via the epigenetic mechanism. Ten BC samples were analyzed for the expression levels of nine genes, six genes, and three genes using the RT-PCR technique. All 18 evaluated genes except for , , and showed weak band expressions in some BC specimens. and were expressed in 40 % of the BC tissue samples, and , , and were expressed in 30 %. The lowest expression levels were found for , , , , , and in 10 % of the BC specimens and for , and in 20 % of the samples. The most frequently expressed gene was (found in 70 % of the BC samples), which suggests that it may serve as - a marker for screening of BC. treatment, the 5-aza-2'-deoxycytidine agent led to a significant rise in mRNA expressions for all tested genes related to the family, except for . By contrast, among the genes in the and families, only and exhibited detectable mRNA expression levels after treatment. - Source: PubMed
Publication date: 2024/07/11
Almatrafi Ahmad MAlamery SalmanAlmutairi Mikhlid H - To overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwent leukapheresis and T-cell product manufacturing. Patients received lymphodepletion, IMA101 infusion and interleukin 2 for 14 days. Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). The most common adverse events were cytokine release syndrome (G1, = 6; G2, = 4) and cytopenia. At 6 weeks, 12 (85.7%) patients had stable disease. Three patients had prolonged disease stabilization for 12.9, 7.3, and 13.7 months, respectively. The median progression-free survival and overall survival were 3.4 months and 9.4 months, respectively. Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation. - Source: PubMed
Publication date: 2023/12/19
Tsimberidou Apostolia MBaysal Mehmet AChakraborty AbhijitAndersson Borje S - The recognition of antigenic peptide-MHC (pMHC) molecules by T-cell receptors (TCR) initiates the T-cell mediated immune response. Structural characterization is key for understanding the specificity of TCR-pMHC interactions and informing the development of therapeutics. Despite the rapid rise of single particle cryoelectron microscopy (cryoEM), x-ray crystallography has remained the preferred method for structure determination of TCR-pMHC complexes. Here, we report cryoEM structures of two distinct full-length α/β TCR-CD3 complexes bound to their pMHC ligand, the cancer-testis antigen HLA-A2/MAGEA4 (230-239). We also determined cryoEM structures of pMHCs containing MAGEA4 (230-239) peptide and the closely related MAGEA8 (232-241) peptide in the absence of TCR, which provided a structural explanation for the MAGEA4 preference displayed by the TCRs. These findings provide insights into the TCR recognition of a clinically relevant cancer antigen and demonstrate the utility of cryoEM for high-resolution structural analysis of TCR-pMHC interactions. - Source: PubMed
Publication date: 2023/04/26
Saotome KeiDudgeon DrewColotti KierstenMoore Michael JJones JenniferZhou YiRafique AshiqueYancopoulos George DMurphy Andrew JLin John COlson William CFranklin Matthew C